Caveolin is known to down-regulate both neuronal (nNOS) and endothelial nitric-oxide synthase (eNOS). In the present study, direct interactions of recombinant caveolin-1 with both the oxygenase and reductase domains of nNOS were demonstrated using in vitro binding assays. To elucidate the mechanism of nNOS regulation by caveolin, we examined the effects of a caveolin-1 scaffolding domain peptide (CaV1p1; residues (82-101)) on the catalytic activities of wild-type and mutant nNOSs. CaV1p1 inhibited NO formation activity and NADPH oxidation of wild-type nNOS in a dose-dependent manner with an IC 50 value of 1.8 M. Mutations of Phe 584 and Trp 587 within a caveolin binding consensus motif of the oxygenase domain did not result in the loss of CaV1p1 inhibition, indicating that an alternate region of nNOS mediates inhibition by caveolin. The addition of CaV1p1 also inhibited more than 90% of the cytochrome c reductase activity in the isolated reductase domain with or without the calmodulin (CaM) binding site, whereas CaV1p1 inhibited ferricyanide reductase activity by only 50%. These results suggest that there are significant differences in the mechanism of inhibition by caveolin for nNOS as compared with those previously reported for eNOS. Further analysis of the interaction through the use of several reductase domain deletion mutants revealed that the FMN domain was essential for successful interaction between caveolin-1 and nNOS reductase. We also examined the effects of CaV1p1 on an autoinhibitory domain deletion mutant (⌬40) and a C-terminal truncation mutant (⌬C33), both of which are able to form NO in the absence of CaM, unlike the wild-type enzyme. Interestingly, CaV1p1 inhibited CaM-dependent, but not CaMindependent, NO formation activities of both ⌬40 and ⌬C33, suggesting that CaV1p1 inhibits interdomain electron transfer induced by CaM from the reductase domain to the oxygenase domain.Nitric-oxide synthase (NOS) 1 generates the physiologically important nitric oxide molecule (NO) from L-arginine (L-Arg) (1-5).NOS consists of two functional domains: an N-terminal oxygenase domain containing a cytochrome P450 (P450)-like heme active site, and L-Arg and (6R)-5,6,7,8-tetrahydrobiopterin (H 4 B) binding sites (6), and a C-terminal reductase domain that contains the FAD, FMN, and NADPH binding sites (7,8). The two domains are connected by a calmodulin (CaM) binding site. Binding of CaM facilitates the interdomain electron transfers required for NO formation as well as intradomain electron transfers within the reductase domain. Two isoforms of NOS (neuronal NOS (nNOS) and endothelial NOS (eNOS)) are constitutively expressed and are regulated by intracellular Ca 2ϩ concentrations via the reversible binding of Ca 2ϩ /CaM (9). In contrast, the inducible NOS isoform (iNOS) is regulated at the transcriptional level, and binds CaM tightly even at basal Ca 2ϩ concentrations (10). CaM-dependent regulation of the three NOS isoforms is also controlled by isoform-specific sequences (i.e. insertions or extensions) and by pho...